Glaukos Co. (NYSE:GKOS) Shares Purchased by WCM Investment Management LLC

WCM Investment Management LLC lifted its position in Glaukos Co. (NYSE:GKOS) by 45.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 99,155 shares of the medical instruments supplier’s stock after purchasing an additional 31,084 shares during the quarter. WCM Investment Management LLC’s holdings in Glaukos were worth $12,721,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in GKOS. Values First Advisors Inc. acquired a new stake in Glaukos during the 3rd quarter worth approximately $25,000. GAMMA Investing LLC lifted its position in Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after acquiring an additional 486 shares during the period. Fifth Third Wealth Advisors LLC acquired a new stake in Glaukos during the 2nd quarter worth approximately $187,000. Brighton Jones LLC acquired a new stake in Glaukos during the 2nd quarter worth approximately $208,000. Finally, Procyon Advisors LLC acquired a new stake in Glaukos during the 3rd quarter worth approximately $210,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Glaukos

In other Glaukos news, Director Marc Stapley sold 6,250 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $125.93, for a total transaction of $787,062.50. Following the completion of the transaction, the director now owns 34,076 shares of the company’s stock, valued at approximately $4,291,190.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, COO Joseph E. Gilliam sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total transaction of $646,800.00. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at $13,216,581.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Marc Stapley sold 6,250 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the sale, the director now owns 34,076 shares in the company, valued at $4,291,190.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,525 shares of company stock valued at $2,142,029 in the last ninety days. Corporate insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

NYSE GKOS opened at $143.02 on Tuesday. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $145.51. The company has a market capitalization of $7.89 billion, a P/E ratio of -47.36 and a beta of 1.02. The business has a 50 day moving average price of $130.07 and a 200 day moving average price of $121.35. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.67.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. During the same period last year, the business posted ($0.50) EPS. Glaukos’s quarterly revenue was up 23.9% on a year-over-year basis. Sell-side analysts expect that Glaukos Co. will post -1.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on GKOS shares. BTIG Research increased their price objective on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Needham & Company LLC increased their target price on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Truist Financial increased their target price on Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Wells Fargo & Company increased their target price on Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Piper Sandler set a $140.00 target price on Glaukos in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $134.55.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.